Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Current and future management options for myelodysplastic syndromes.

Bryan J, Jabbour E, Prescott H, Garcia-Manero G, Issa JP, Kantarjian H.

Drugs. 2010 Jul 30;70(11):1381-94. doi: 10.2165/11537920-000000000-00000. Review.

PMID:
20614946
2.

Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.

Ishikawa T.

Int J Clin Oncol. 2014 Feb;19(1):10-5. doi: 10.1007/s10147-013-0651-5. Epub 2013 Dec 20. Review.

PMID:
24357411
3.

Novel therapies for myelodysplastic syndromes.

Steensma DP.

Hematol Oncol Clin North Am. 2010 Apr;24(2):423-41. doi: 10.1016/j.hoc.2010.02.010. Review.

PMID:
20359635
4.

More is better: combination therapies for myelodysplastic syndromes.

Ornstein MC, Mukherjee S, Sekeres MA.

Best Pract Res Clin Haematol. 2015 Mar;28(1):22-31. doi: 10.1016/j.beha.2014.11.002. Epub 2014 Nov 11. Review.

PMID:
25659727
5.

Risk-based management of myelodysplastic syndrome.

Steensma DP, Tefferi A.

Oncology (Williston Park). 2007 Jan;21(1):43-54; discussion 57-8, 62. Review.

6.

[Supportive therapy for myelodysplastic syndrome (MDS). Indispensable pillar in the multimodal treatment concept].

Göbel A, Lubrich B.

Pharm Unserer Zeit. 2010 May;39(3):228-33. doi: 10.1002/pauz.201000370. Review. German. No abstract available.

PMID:
20425777
7.

The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.

Greenberg PL, Cosler LE, Ferro SA, Lyman GH.

J Natl Compr Canc Netw. 2008 Oct;6(9):942-53.

PMID:
18926103
8.

Update on the pharmacotherapy for myelodysplastic syndromes.

Duong VH, Komrokji RS, List AF.

Expert Opin Pharmacother. 2014 Sep;15(13):1811-25. doi: 10.1517/14656566.2014.937705. Epub 2014 Jul 31. Review.

PMID:
25080144
9.

Pharmacotherapy of myelodysplastic syndromes.

Galili N, Raza A.

Expert Opin Pharmacother. 2010 Aug;11(11):1889-99. doi: 10.1517/14656566.2010.485613. Review.

PMID:
20486832
10.

Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?

Leitch HA, Vickars LM.

Hematology Am Soc Hematol Educ Program. 2009:664-72. doi: 10.1182/asheducation-2009.1.664. Review.

PMID:
20008252
11.

Deacetylase inhibitors for the treatment of myelodysplastic syndromes.

Jabbour E, Garcia-Manero G.

Leuk Lymphoma. 2015 May;56(5):1205-12. doi: 10.3109/10428194.2014.946025. Epub 2015 Feb 24. Review.

PMID:
25058371
12.

Hematopoietic growth factors in myelodysplastic syndromes.

Steensma DP.

Semin Oncol. 2011 Oct;38(5):635-47. doi: 10.1053/j.seminoncol.2011.04.014. Review.

PMID:
21943670
13.

Hypomethylating agents and other novel strategies in myelodysplastic syndromes.

Garcia-Manero G, Fenaux P.

J Clin Oncol. 2011 Feb 10;29(5):516-23. doi: 10.1200/JCO.2010.31.0854. Epub 2011 Jan 10. Review.

14.

New agents in myelodysplastic syndromes.

Jabbour EJ, Giles FJ.

Curr Hematol Rep. 2005 May;4(3):191-9. Review.

PMID:
15865871
15.

Treatment of MDS: something old, something new, something borrowed...

Sekeres MA.

Hematology Am Soc Hematol Educ Program. 2009:656-63. doi: 10.1182/asheducation-2009.1.656. Review.

PMID:
20008251
16.

Epigenetic regulation in myelodysplastic syndromes: implications for therapy.

Vigna E, Recchia AG, Madeo A, Gentile M, Bossio S, Mazzone C, Lucia E, Morabito L, Gigliotti V, Stefano LD, Caruso N, Servillo P, Franzese S, Fimognari F, Bisconte MG, Gentile C, Morabito F.

Expert Opin Investig Drugs. 2011 Apr;20(4):465-93. doi: 10.1517/13543784.2011.559164. Epub 2011 Mar 8. Review.

PMID:
21381982
17.

The lower risk MDS patient at risk of rapid progression.

Mittelman M, Oster HS, Hoffman M, Neumann D.

Leuk Res. 2010 Dec;34(12):1551-5. doi: 10.1016/j.leukres.2010.05.023. Epub 2010 Jun 22. Review.

PMID:
20573398
18.

Novel biospecific agents for the treatment of myelodysplastic syndromes.

Gotlib J, Greenberg PL.

J Natl Compr Canc Netw. 2003 Oct;1(4):473-80. Review.

PMID:
19774739
19.

Targeted therapies in myelodysplastic syndrome.

Melchert M, List A.

Semin Hematol. 2008 Jan;45(1):31-8. doi: 10.1053/j.seminhematol.2007.10.001.

PMID:
18179967
20.

Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?

DeZern AE.

Hematology Am Soc Hematol Educ Program. 2015;2015:308-16. doi: 10.1182/asheducation-2015.1.308.

PMID:
26637738

Supplemental Content

Support Center